Connect with us

Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website. .

Top Stories

Novo Nordisk’s controlling shareholder plans to invest up to $7 billion a year by 2030 – FT

2024 02 12T055011Z 1 LYNXNPEK1B047 RTROPTP 4 NOVO HOLDINGS INVESTMENT scaled - Global Banking | Finance

Novo Nordisk’s controlling shareholder plans to invest up to $7 billion a year by 2030 – FT

(Reuters) – Novo Holdings, the controlling shareholder of Danish obesity drugmaker Novo Nordisk, plans to invest up to $7 billion annually by 2030, the Financial Times reported on Monday.

Kasim Kutay, chief executive of Novo Holdings, told the newspaper that income from its 28% stake in Novo Nordisk and other investments would give the fund $5 billion a year to invest in the next five years.

“We’ve got an ever growing investment portfolio that’s generating very attractive returns,” FT quoted Kutay as saying.

“That’s going to keep on growing, then we’ve got obviously the growth of . . . Ozempic and Wegovy and a lot of dividends . . . we have more money than ever to invest,” he said.

Novo Holdings has 77% of voting shares in Novo Nordisk, the maker of blockbuster obesity drug Wegovy and diabetes treatment Ozempic.

The move comes soon after Novo Holdings, the investment arm of Novo’s controlling shareholder, the Novo Nordisk Foundation, last week said it would buy Catalent, a key manufacturing subcontractor, for $16.5 billion.

Novo Holdings did not immediately respond to a request for comment asking where it would invest the funds.


(Reporting by Mrinmay Dey in Bengaluru; Editing by Janane Venkatraman and Sonia Cheema)


Global Banking & Finance Review


Why waste money on news and opinions when you can access them for free?

Take advantage of our newsletter subscription and stay informed on the go!

By submitting this form, you are consenting to receive marketing emails from: Global Banking & Finance Review │ Banking │ Finance │ Technology. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

Recent Post